Boehringer Ingelheim GMBH’s acquisition of Hanmi Pharmaceutical Co. Ltd.’s third-generation EGFR inhibitor HM61713 helps the German company build its oncology presence with an essential asset in the targeted lung cancer space, but the Phase II candidate has a lot of catching up to do.
Boehringer Joins Next Generation Via Hanmi EGFR Inhibitor Deal
Hanmi’s third-generation EGFR inhibitor HM61713, acquired for $50 million up front, strongly complements Boehringer’s Gilotrif/Giotrif, but the new asset is far behind competitors from AstraZeneca and Clovis.